The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.
This is likely due to fewer product launches and lower price increases.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.
A new study found that orphan drug spending will slow through 2018; senators open inquiry into Mylan; Shires launches branded campaign
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Specialty medicines will keep drug spend trending upward through the next five years.
Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.